Article

(2019) Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with nonalcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial. Nutrition & Metabolism. p. 13. ISSN 1743-7075

(2018) The nanocurcumin reduces appetite in obese patients with non-alcoholic fatty liver disease (nafld): a double-blind randomized placebo-controlled clinical trial. Nanomedicine Journal. pp. 67-76. ISSN 2322-3049

(2017) Efficacy of nanocurcumin supplementation on insulin resistance, lipids, inflammatory factors and nesfatin among obese patients with non-alcoholic fatty liver disease (NAFLD): a trial protocol. Bmj Open. p. 7. ISSN 2044-6055

(2016) Ethosomal Curcumin Promoted Wound Healing and Reduced Bacterial Flora in Second Degree Burn in Rat. Drug Research. pp. 660-665. ISSN 2194-9379